E. coli uses serine to abide acidity
Mar. 23, 2023—Vanderbilt researchers have discovered another acid resistance mechanism for UTI-causing E. coli, laying the foundation for targeted antibacterial therapies.
Study seeks to identify prenatal allergy risk markers
Mar. 16, 2023—A Vanderbilt clinical trial is seeking to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis, or eczema, as well as biological pathways that lead to these conditions.
Diabetes drug may improve asthma
Feb. 21, 2023—New biomarker finding strengthens the case for using GLP-1R agonists to treat patients with Type 2 diabetes who also suffer from asthma.
COVID-19 battle begins in the nose
Feb. 2, 2023—A high upper airway concentration of the virus that causes COVID-19 was associated with changes in gene expression that could impact disease progression, Vanderbilt researchers discovered.
Study identifies potential new approach for treating lupus
Jan. 13, 2023—A Vanderbilt study found that targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus — the most common form of the chronic autoimmune disease lupus.
Researchers develop framework for multiancestry genomic studies
Dec. 8, 2022—Vanderbilt researchers have developed a framework for the analysis of multiancestry, large-scale genomic studies across multiple biobanks.
Clinical trial at VUMC tests novel treatment for asthma
Nov. 10, 2022—VUMC has begun enrolling patients with asthma in a clinical trial of a novel treatment: a medication approved to treat diabetes and obesity.
C. diff infections drop in children
Nov. 3, 2022—The number of pediatric infections caused by Clostridioides difficile (C. diff) decreased from 2013 to 2019, likely due to an increase in antibiotic stewardship programs and improved hospital contact protocols, Vanderbilt researchers found.
Enhancing innate immunity in the lung
Sep. 12, 2022—Vanderbilt researchers show that a TLR4 agonist improves lung immune response and survival in a mouse model of bacterial pneumonia, supporting the development of this drug to protect against pneumonia in hospitalized patients.
Study identifies key player in T cell “education”
Sep. 1, 2022—New Vanderbilt research could inform therapeutic strategies for enhancing thymic function when desired — such as during aging, recovery from radiation therapy or chemotherapy, or other conditions that reduce T cell output.
Vanderbilt researchers discover how gut inflammation leads to bone loss
Aug. 25, 2022—Gastrointestinal inflammation, such as occurs in inflammatory bowel disease, triggers the expansion of a population of “bone-eating” cells, leading to bone loss.
Study describes how E. coli co-opts cells, causes recurrent UTIs
Aug. 25, 2022—Researchers at Vanderbilt University Medical Center have discovered why the uropathogenic bacterium E. coli, the leading cause of urinary tract infections, is so tenacious; their findings could lead to new ways to prevent recurrent UTIs.